News | April 16, 2026
Rubicon forays into India's CNS segment with Rs 175.92 crore Arinna buy
Acquires 85% stake in the formulations company valued at Rs 200 crore enterprise value; founder Vivek Seth to retain 15%
Acquires 85% stake in the formulations company valued at Rs 200 crore enterprise value; founder Vivek Seth to retain 15%
Former Wavemaker executive to lead media strategy and digital transformation agenda
To boost compostable packaging, resin innovation, and supply chain speed
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
A brand from Opella will be part of the official NASA astronaut formulary
Drugmaker taps 1 million retail touchpoints, quick commerce and modern trade to expand ingredient-led skincare franchise
20 among them to receive $20,000 grants
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
The India FMCG business showed a sequential recovery and is expected to post high-single digit growth
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
Subscribe To Our Newsletter & Stay Updated
